Absci Corp
NASDAQ:ABSI
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.39
6.585
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Absci Corp
Absci Corp
PP&E Net
Absci Corp
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Absci Corp
NASDAQ:ABSI
|
PP&E Net
$45.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
PP&E Net
$9.4B
|
CAGR 3-Years
10%
|
CAGR 5-Years
13%
|
CAGR 10-Years
15%
|
|
|
Danaher Corp
NYSE:DHR
|
PP&E Net
$6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
|
Mettler-Toledo International Inc
NYSE:MTD
|
PP&E Net
$790.4m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
4%
|
|
|
Agilent Technologies Inc
NYSE:A
|
PP&E Net
$1.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
14%
|
CAGR 10-Years
4%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
PP&E Net
$772m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
15%
|
|
Absci Corp
Glance View
Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. The company is headquartered in Vancouver Washington, Washington and currently employs 216 full-time employees. The company went IPO on 2021-07-22. The firm has developed an Integrated Drug Creation platform to identify novel drug targets, discover biotherapeutic candidates, and generate the cell lines to manufacture them in a single process. The company uses synthetic biology technologies and deep learning artificial intelligence (AI) to predict, identify, design, construct, screen, select and scale production of biologic drug candidates, and learn from the data it generates. The firm has drug candidates in approximately nine active programs, eight of the active programs are focused on developing production cell lines for drug candidates that the Company's partners are developing. The company has one discovery program, focused on lead optimization with Astellas. The Company’s active programs include Bispecific monoclonal antibodies (mAb), Bispecific T-cell engager, Cytokine, Fab, Multivalent Fc-fusion, Plasma protein and mAb.
See Also
What is Absci Corp's PP&E Net?
PP&E Net
45.8m
USD
Based on the financial report for Dec 31, 2023, Absci Corp's PP&E Net amounts to 45.8m USD.
What is Absci Corp's PP&E Net growth rate?
PP&E Net CAGR 3Y
51%
Over the last year, the PP&E Net growth was -21%. The average annual PP&E Net growth rates for Absci Corp have been 51% over the past three years .
You don't have any saved screeners yet
